Woman of the Week: Psilera’s Jackie von Salm
PharmaVoice
MARCH 29, 2023
Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm
PharmaVoice
MARCH 29, 2023
Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm
Fierce Healthcare
MARCH 29, 2023
Signify Health CEO says CVS deal will 'turbocharge' home health provider's roadmap hlandi Wed, 03/29/2023 - 19:57
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 27, 2023
BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers fkansteiner Mon, 03/27/2023 - 09:35
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
PharmaVoice
MARCH 28, 2023
The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market
Fierce Healthcare
MARCH 29, 2023
UnitedHealthcare to begin reducing prior authorizations this summer pminemyer Wed, 03/29/2023 - 17:02
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 29, 2023
Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.
Fierce Pharma
MARCH 27, 2023
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries esagonowsky Mon, 03/27/2023 - 09:19
Fierce Healthcare
MARCH 28, 2023
ViVE 2023: Amazon Pharmacy integrates coupons in latest bid to target affordability of branded drugs hlandi Tue, 03/28/2023 - 15:24
Pharmafile
MARCH 27, 2023
The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter clinical trial design. read more Medical Communications
Pharmaceutical Technology
MARCH 29, 2023
Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases.
Fierce Pharma
MARCH 27, 2023
Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio zbecker Mon, 03/27/2023 - 17:42
Fierce Healthcare
MARCH 27, 2023
ViVE 2023: UnitedHealth's new tech exec on how the payer giant is aiming to accelerate transformation pminemyer Mon, 03/27/2023 - 22:48
Pharmafile
MARCH 29, 2023
Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy of anti-netrin-1 antibody NP137 in combination with mFOLFIRINOX as a first-line treatment for patients with locally advanced pancreatic ductal adenocarcinoma.
Pharmaceutical Technology
MARCH 27, 2023
Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).
Fierce Pharma
MARCH 27, 2023
Look out, Lilly. Novartis touts 'consistent benefit' for Kisqali in broad early-stage breast cancer aliu Mon, 03/27/2023 - 10:51
Fierce Healthcare
MARCH 28, 2023
Hospitals feel congressional heat over compliance with price transparency rule rking Tue, 03/28/2023 - 17:11
European Pharmaceutical Review
MARCH 29, 2023
Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer.
Pharmaceutical Technology
MARCH 28, 2023
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D).
Fierce Pharma
MARCH 28, 2023
Another rare disease M&A deal? BridgeBio draws buyout interest from Big Pharma: Bloomberg aliu Tue, 03/28/2023 - 10:22
Fierce Healthcare
MARCH 27, 2023
Value-based care enabler Wellvana clinches $84M to expand in existing, new markets agliadkovskaya Mon, 03/27/2023 - 14:48
Pharmafile
MARCH 29, 2023
Genialis, a computational precision medicine company, has announced that it’s raised more than $13m in Series A funding, co-led by Taiwania Capital and Debiopharm Innovation Fund.
Pharmaceutical Technology
MARCH 29, 2023
On March 28, the UK government announced that four UK life sciences companies will receive £277 million to help fund and advance manufacturing projects in medical diagnostics and human medicines.
Fierce Pharma
MARCH 27, 2023
With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug kdunleavy Mon, 03/27/2023 - 10:40
Fierce Healthcare
MARCH 29, 2023
Bipartisan Senate bill aims to take on Medicare Advantage up-coding practices rking Wed, 03/29/2023 - 17:02
Pharmafile
MARCH 29, 2023
AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus (SLE).
PharmaVoice
MARCH 28, 2023
Ahead of turbulent market conditions, EY analyst Arda Ural encourages companies to rethink their sales strategy
Fierce Pharma
MARCH 27, 2023
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda aliu Mon, 03/27/2023 - 15:40
Fierce Healthcare
MARCH 28, 2023
ViVe 2023: CancerX co-hosts Moffitt Cancer Center, Digital Medicine Society, unveil 'Moonshot' digital health effort hlandi Tue, 03/28/2023 - 07:36
Pharmafile
MARCH 28, 2023
Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily oral semaglutide 25mg and 50mg versus 14mg as an add-on to a stable dose of 1-3 oral antidiabetic medicines in patients with type 2 diabetes.
Pharmaceutical Commerce
MARCH 30, 2023
Deciphering the different "technology-first” and “technology-enabled” patient support programs.
Fierce Pharma
MARCH 28, 2023
FDA committee will hear Perrigo's OTC bid for birth control med Opill in May kdunleavy Tue, 03/28/2023 - 14:47
Fierce Healthcare
MARCH 28, 2023
Podnosis': Insight on the Ohio train derailment class-action lawsuit, and how data analytics can improve social risk factor identification tcarey Tue, 03/28/2023 - 14:07
Pharmafile
MARCH 27, 2023
Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco Bay Area biotech incubator network.
Pharmaceutical Commerce
MARCH 30, 2023
With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Fierce Pharma
MARCH 29, 2023
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications kdunleavy Wed, 03/29/2023 - 10:40
Let's personalize your content